Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Zatloukal, Petr [VerfasserIn]   i
 Cardenal, F. [VerfasserIn]   i
 Szczesna, A. [VerfasserIn]   i
 Gorbunova, V. [VerfasserIn]   i
 Moiseyenko, V. [VerfasserIn]   i
 Zhang, X. [VerfasserIn]   i
 Cisar, L. [VerfasserIn]   i
 Soria, J. -C. [VerfasserIn]   i
 Domine, M. [VerfasserIn]   i
 Thomas, Michael [VerfasserIn]   i
Titel:A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease
Verf.angabe:P. Zatloukal, F. Cardenal, A. Szczesna, V. Gorbunova, V. Moiseyenko, X. Zhang, L. Cisar, J. -C. Soria, M. Domine & M. Thomas
E-Jahr:2010
Jahr:September 2010
Umfang:7 S.
Illustrationen:1 Diagramm
Fussnoten:Gesehen am 17.04.2024
Titel Quelle:Enthalten in: Annals of oncology
Ort Quelle:Amsterdam [u.a.] : Elsevier, 1990
Jahr Quelle:2010
Band/Heft Quelle:21(2010), 9 vom: Sept., Seite 1810-1816
ISSN Quelle:1569-8041
Abstract:Background - This study compared irinotecan plus cisplatin (IP) with etoposide plus cisplatin (EP) in small-cell lung cancer patients with extensive disease. - Patients and methods - Patients were randomly assigned to receive cisplatin 80 mg/m2 and either irinotecan 65 mg/m2, days 1 and 8 or etoposide 100 mg/m2, days 1-3, every 3 weeks. - Results - Baseline characteristics were balanced between patients receiving IP (N = 202) or EP (N = 203). Median overall survival was nonsignificantly superior for patients receiving IP versus EP, 10.2 versus 9.7 months [hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.65-1.01, P = 0.06] and 1- and 2-year survival rates were 41.9% versus 38.9% and 16.3% versus 8.2%, respectively. Noninferiority of IP versus EP was established, upper bound of the 95% CI of HR 1.01 (prespecified margin IP/EP <1.25). Overall response (39.1% versus 46.6%) and time to tumor progression (5.4 versus 6.2 months) were not superior for IP. Grade 3/4 vomiting (10.9% versus 4.4%) and diarrhea (15.4% versus 0.5%) were more common in the IP versus EP arm; grade 3/4 neutropenia was more frequent in the EP (59.6%) versus IP arm (38.1%). - Conclusions - Our data demonstrate the noninferiority of IP versus EP for survival in primarily Western patients with SCLC-ED. A meta-analysis is required to finally assess the role of irinotecan in this setting.
DOI:doi:10.1093/annonc/mdq036
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1093/annonc/mdq036
 Volltext: https://www.sciencedirect.com/science/article/pii/S0923753419400598
 DOI: https://doi.org/10.1093/annonc/mdq036
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:cisplatin
 etoposide
 irinotecan
 small-cell lung cancer with extensive disease
K10plus-PPN:1886034699
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69205099   QR-Code
zum Seitenanfang